vs

Side-by-side financial comparison of ALLIANCE ENTERTAINMENT HOLDING CORP (AENT) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

ALLIANCE ENTERTAINMENT HOLDING CORP is the larger business by last-quarter revenue ($368.7M vs $207.3M, roughly 1.8× Ultragenyx Pharmaceutical Inc.). ALLIANCE ENTERTAINMENT HOLDING CORP runs the higher net margin — 2.5% vs -62.0%, a 64.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -6.3%). ALLIANCE ENTERTAINMENT HOLDING CORP produced more free cash flow last quarter ($-16.9M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 32.1%).

Alliance Atlantis Communications Inc. was a media company that operated primarily as a specialty service provider in Canada. Primarily based in Toronto, Alliance Atlantis also had offices in Halifax, Los Angeles, London, Dublin, Madrid, Barcelona, Shannon, and Sydney.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

AENT vs RARE — Head-to-Head

Bigger by revenue
AENT
AENT
1.8× larger
AENT
$368.7M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+32.2% gap
RARE
25.9%
-6.3%
AENT
Higher net margin
AENT
AENT
64.6% more per $
AENT
2.5%
-62.0%
RARE
More free cash flow
AENT
AENT
$83.9M more FCF
AENT
$-16.9M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
32.1%
AENT

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AENT
AENT
RARE
RARE
Revenue
$368.7M
$207.3M
Net Profit
$9.4M
$-128.6M
Gross Margin
Operating Margin
4.7%
-54.7%
Net Margin
2.5%
-62.0%
Revenue YoY
-6.3%
25.9%
Net Profit YoY
32.8%
3.5%
EPS (diluted)
$0.18
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AENT
AENT
RARE
RARE
Q4 25
$368.7M
$207.3M
Q3 25
$254.0M
$159.9M
Q2 25
$227.8M
$166.5M
Q1 25
$213.0M
$139.3M
Q4 24
$393.7M
$164.6M
Q3 24
$229.0M
$139.5M
Q2 24
$236.9M
$147.0M
Q1 24
$211.2M
$108.8M
Net Profit
AENT
AENT
RARE
RARE
Q4 25
$9.4M
$-128.6M
Q3 25
$4.9M
$-180.4M
Q2 25
$5.8M
$-115.0M
Q1 25
$1.9M
$-151.1M
Q4 24
$7.1M
$-133.2M
Q3 24
$397.0K
$-133.5M
Q2 24
$2.5M
$-131.6M
Q1 24
$-3.4M
$-170.7M
Operating Margin
AENT
AENT
RARE
RARE
Q4 25
4.7%
-54.7%
Q3 25
4.2%
-106.9%
Q2 25
4.3%
-64.8%
Q1 25
1.7%
-102.6%
Q4 24
3.8%
-74.3%
Q3 24
0.9%
-94.6%
Q2 24
0.2%
-79.1%
Q1 24
-0.3%
-151.9%
Net Margin
AENT
AENT
RARE
RARE
Q4 25
2.5%
-62.0%
Q3 25
1.9%
-112.8%
Q2 25
2.5%
-69.0%
Q1 25
0.9%
-108.5%
Q4 24
1.8%
-80.9%
Q3 24
0.2%
-95.7%
Q2 24
1.1%
-89.5%
Q1 24
-1.6%
-156.8%
EPS (diluted)
AENT
AENT
RARE
RARE
Q4 25
$0.18
$-1.28
Q3 25
$0.10
$-1.81
Q2 25
$0.11
$-1.17
Q1 25
$0.04
$-1.57
Q4 24
$0.14
$-1.34
Q3 24
$0.01
$-1.40
Q2 24
$0.05
$-1.52
Q1 24
$-0.07
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AENT
AENT
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$117.6M
$-80.0M
Total Assets
$434.1M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AENT
AENT
RARE
RARE
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$127.1M
Q4 24
$174.0M
Q3 24
$4.3M
$150.6M
Q2 24
$1.1M
$480.7M
Q1 24
$1.6M
$112.3M
Stockholders' Equity
AENT
AENT
RARE
RARE
Q4 25
$117.6M
$-80.0M
Q3 25
$108.1M
$9.2M
Q2 25
$103.2M
$151.3M
Q1 25
$97.4M
$144.2M
Q4 24
$95.6M
$255.0M
Q3 24
$88.0M
$346.8M
Q2 24
$87.6M
$432.4M
Q1 24
$85.1M
$140.3M
Total Assets
AENT
AENT
RARE
RARE
Q4 25
$434.1M
$1.5B
Q3 25
$383.0M
$1.2B
Q2 25
$361.2M
$1.3B
Q1 25
$349.4M
$1.3B
Q4 24
$401.7M
$1.5B
Q3 24
$395.7M
$1.5B
Q2 24
$340.8M
$1.6B
Q1 24
$324.0M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AENT
AENT
RARE
RARE
Operating Cash FlowLast quarter
$-16.5M
$-99.8M
Free Cash FlowOCF − Capex
$-16.9M
$-100.8M
FCF MarginFCF / Revenue
-4.6%
-48.6%
Capex IntensityCapex / Revenue
0.1%
0.5%
Cash ConversionOCF / Net Profit
-1.76×
TTM Free Cash FlowTrailing 4 quarters
$-1.4M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AENT
AENT
RARE
RARE
Q4 25
$-16.5M
$-99.8M
Q3 25
$2.7M
$-91.4M
Q2 25
$10.7M
$-108.3M
Q1 25
$2.5M
$-166.5M
Q4 24
$25.3M
$-79.3M
Q3 24
$-11.6M
$-67.0M
Q2 24
$9.7M
$-77.0M
Q1 24
$20.0M
$-190.7M
Free Cash Flow
AENT
AENT
RARE
RARE
Q4 25
$-16.9M
$-100.8M
Q3 25
$2.4M
$-92.7M
Q2 25
$10.7M
$-110.7M
Q1 25
$2.4M
$-167.8M
Q4 24
$-79.5M
Q3 24
$-11.6M
$-68.6M
Q2 24
$-79.0M
Q1 24
$20.0M
$-193.9M
FCF Margin
AENT
AENT
RARE
RARE
Q4 25
-4.6%
-48.6%
Q3 25
0.9%
-58.0%
Q2 25
4.7%
-66.5%
Q1 25
1.1%
-120.5%
Q4 24
-48.3%
Q3 24
-5.1%
-49.2%
Q2 24
-53.7%
Q1 24
9.4%
-178.2%
Capex Intensity
AENT
AENT
RARE
RARE
Q4 25
0.1%
0.5%
Q3 25
0.1%
0.8%
Q2 25
0.0%
1.5%
Q1 25
0.0%
1.0%
Q4 24
0.0%
0.1%
Q3 24
0.0%
1.2%
Q2 24
1.4%
Q1 24
0.0%
3.0%
Cash Conversion
AENT
AENT
RARE
RARE
Q4 25
-1.76×
Q3 25
0.56×
Q2 25
1.86×
Q1 25
1.33×
Q4 24
3.57×
Q3 24
-29.31×
Q2 24
3.85×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AENT
AENT

Segment breakdown not available.

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons